We help biopharma leadership teams turn fragmented data into sharper strategy, precise resource allocation, and confident executive action.
Pharma does not lack data; it lacks clarity. We are a specialized advisory firm bridging the gap between massive data telemetry and the specific strategic choices that drive commercial growth.
Dashboard overload and fragmented logic.
Commercial teams subscribe to vast amounts of claims, CRM, and syndicated data. Yet when a launch stalls or growth flattens, leadership receives generic reporting highlighting *what* happened last quarter, failing to provide causal answers or clear strategic direction.
Actionable commercial intelligence.
We frame the exact business constraint first. By isolating the problem and pointing bespoke analytics directly at it, we deliver specific answers that leadership can immediately translate into resource allocation and field execution.
Review Operating ModelWe organize our expertise around the most critical business problems our clients face. We apply the right data, analytics, and strategic framing to execute the solution.
We help leadership teams connect complex analytics directly to strategic choices. Before touching data, we frame the commercial landscape, define the constraints, and establish clear criteria for market entry, portfolio prioritization, and resource allocation.
Moving beyond simple volume deciling, we build sophisticated behavioral profiles of prescribers and accounts. We analyze referral networks, institutional influence, and historical adoption patterns to identify the physicians most likely to drive meaningful volume uplift.
Launch windows are brief and unforgiving. We build specialized tracking systems that monitor early signals of adoption, identify specific market access friction points, and give leadership the clarity required to reallocate field resources before a trajectory flattens.
We transform raw, fragmented claims and EMR data into coherent patient journeys. By analyzing diagnostic timing, treatment sequencing, and compliance drops, we identify exactly where intervention will have the greatest impact on outcomes.
We build rigorous mathematical models that move beyond static spreadsheet assumptions. Using probabilistic simulation and advanced machine learning, we help executives evaluate risk, value pipeline assets, and set defensible expectations.
We do not sell multi-year transformation programs. We sell clarity. We believe the most effective way to prove value is to solve a single, complex commercial problem quickly.
We define the business question, outline the constraints, and translate the commercial problem into measurable analytical hypotheses.
We develop the analytical approach and work in short, focused 2-4 week cycles. We test assumptions directly against your enterprise data landscape.
We present a verified executive decision ledger. We do not deliver black-box models. We deliver clear recommendations ready for senior sign-off.
Once proven, we operationalize the logic. Outputs pipe directly into your existing Veeva CRM, Snowflake, or Databricks infrastructure for field execution.
We operate under stringent legal and operational frameworks to protect client telemetry. We sign standard Third-Party Agreements (TPA), BAA, and operate in full compliance with HIPAA and SOC2 Type II standards. Our agentic models utilize zero-retention parameters, ensuring your launch strategy never trains a public model.
A dossier of strategic analogs detailing how we isolate complex commercial bottlenecks, apply deterministic analytics, and drive executive action.
Applying Positive-Unlabeled (PU) machine learning to fragmented claims datasets to identify high-probability patient cohorts where true negative labels do not exist.
In rare disease markets (e.g., lysosomal storage disorders or rare oncologic mutations), official ICD-10 diagnostic coding is chronically delayed or entirely absent in real-world data. Commercial teams struggle to deploy field forces efficiently because they cannot definitively identify where undiagnosed patients reside.
Traditional supervised machine learning requires both confirmed 'positive' and confirmed 'negative' patients to train a predictive model. However, in claims data, an un-coded patient is not definitively 'negative'—they are merely 'unlabeled'. Forcing traditional binary classifiers onto this environment leads to severe model bias, artificially suppressing the identification of legitimate, symptomatic patients.
We deployed an Elkan-Noto based Positive-Unlabeled (PU) Learning framework across a longitudinal claims dataset (50M+ lives). Rather than assuming un-coded patients were negative, the model treated them as a mixed distribution of hidden positives and true negatives. We isolated highly confident 'true negatives' (patients with mutually exclusive diagnoses) and trained a Gradient Boosting ensemble to assign a latent probability score to the remaining 'unlabeled' mass based on longitudinal symptom phenotypes.
The PU framework successfully identified 4,200 "look-alike" high-risk patients lacking the formal ICD-10 code but displaying identical symptom trajectories to confirmed patients. Commercial leadership instantly routed these unmasked HCP targets to specialized field teams, yielding a 31% uplift in diagnostic testing requisitions within 90 days.
Utilizing sequence-based machine learning on longitudinal Rx/Dx telemetry to predict disease progression 6-12 months before standard clinical diagnosis.
For progressive neurological therapies, early intervention is critical to preserving irreversible functional loss. The optimal time to engage a physician with disease awareness is months before the patient exhibits late-stage symptoms.
Physicians frequently fail to officially diagnose the condition until severe symptoms emerge. Commercial marketing efforts tied solely to formal diagnostic claim codes were activating far too late in the patient timeline, resulting in suboptimal clinical outcomes and lost market share to established generic stop-gaps.
We bypassed cross-sectional static models and engineered a Recurrent Neural Network (RNN) architecture designed specifically for sparse, irregular time-series healthcare data. By embedding thousands of distinct medical interventions, lab orders, and minor procedural codes, the model learned the complex temporal sequence signatures that consistently precede clinical onset by 8 to 12 months.
Marketing strategy successfully pivoted from 'post-diagnosis' engagement to 'pre-disease' unbranded awareness. By deploying highly targeted peer-to-peer (P2P) education to HCPs actively managing flagged high-probability cohorts, the brand accelerated diagnosis timeframes by an average of 4.2 months across the target population.
Deconvoluting regional patient hand-offs and applying graph analytics to locate hidden community prescriber influence sinks driving biologic uptake.
A specialized oncology field team was deploying vast, expensive resources against high-decile Key Opinion Leaders (KOLs) at major academic medical hubs based on historical influence metrics.
Localized script tracking revealed a structural gap: these academic KOLs rarely wrote the initial prescription. They were acting as surgical or second-opinion validators. Following validation, the actual treatment initiation and ongoing script volume fell back into a highly diffuse, untracked web of regional community hematologists.
We ingested millions of deterministic claims pathways to construct a weighted directed graph of patient movement. Applying a modified PageRank algorithm and Louvain community detection, we bypassed basic decile math to isolate the 'true influence sinks'—highly connected community oncologists who routinely received validated patients from KOLs and initiated the long-term infusion regimens.
The commercial blueprint was rewritten. Tier-1 access resources were shifted away from academic validators (retaining only medical affairs liaison support) and directly embedded into the 15% of community nodes that controlled 80% of actual treatment initiation weight, drastically reducing script abandonment post-KOL consult.
Integrating sub-national P&T formulary approvals and HCP trial-decay logic to predict launch stall curves, enabling decisive resource reallocation at Week 12.
At Week 12 of a high-profile immunology launch, top-line NBRx (New-to-Brand Prescriptions) appeared to perfectly match expected street targets. Executive dashboards indicated a successful, on-track launch phase.
Standard volume reporting masked a critical underlying dynamic: heavy initial 'trialing' by early adopters was hiding a near-total failure of 'repeat' prescribing. Without repeat scripts, the mathematical reality guaranteed a severe trajectory cliff early in Quarter 2, putting the asset's entire fiscal year at risk.
We replaced static linear forecasts with a Bayesian hierarchical model combining early leading indicators: P&T committee meeting velocity, localized access hurdles (Prior Auth rejection logs), and HCP trial-to-repeat conversion rates. The simulation deterministically proved the launch curve would stall at 40% below estimates due to regional administrative access friction dampening repeat clinical adoption.
Armed with quantitative proof, leadership executed a "Code Red" field redirection. Dedicated market access personnel were stripped from low-friction zones and flooded into localized P&T friction hotspots, smoothing authorization pathways. The intervention averted the forecasted cliff, securing a $120M annual recurring run-rate trajectory.
Moving beyond naive deciling by estimating heterogeneous treatment effects (Uplift) to direct expensive rep visits exclusively to persuadable targets.
Traditional commercial deployment universally relies on simple volume deciling: identifying the highest volume prescribers in a territory and maximizing physical sales rep frequency against them.
Volume does not equal persuadability. This legacy model results in massive wasted spend by calling on "Sure Things" (brand loyalists who prescribe regardless of rep interaction) and "Lost Causes" (competitor loyalists who will never switch). The objective must shift from volume prediction to response elasticity prediction.
We applied a Double Machine Learning causal inference framework to historic CRM interaction logs joined with longitudinal Rx outputs. By estimating the Heterogeneous Treatment Effect (HTE) of a physical field visit versus an email interaction, the model assigned an "Uplift Score" to every physician. Non-linear integer programming then mapped the constrained field force strictly to the highly elastic "Persuadable" quadrant.
The revised commercial blueprint isolated 22% of historical Tier-1 targets as "Sure Things" and shifted them entirely to automated digital channels with zero negative impact on volume. The unlocked field capacity was hyper-concentrated onto mid-decile "Persuadables," generating a measured 18% net-new Rx volume lift with no additional commercial headcount.
Constructing a deterministic journey waterfall to pinpoint the exact days where diagnosed patients abandon treatment due to administrative access friction.
A specialty brand targeting a rare mutation observed acceptable diagnostic testing volumes, but lower-than-expected commercial fulfillment rates. The conversion pipeline from a positive NGS reflex test to an active, reimbursed commercial patient was failing.
Standard syndicated data provided no granularity into the complex 6-week onboarding window. Leadership could see patients entering the funnel (Dx) and the few exiting it (Rx), but had zero visibility into exactly where, when, and why the majority were abandoning therapy in the middle.
We engineered a deterministic patient journey waterfall utilizing rigorous survival analysis techniques. By linking probabilistic ICD-10 diagnostic coding, lab NGS reflex testing logs, and downstream 867 specialty pharmacy feeds, we calculated exact Kaplan-Meier abandonment probabilities at every micro-step of the access journey.
The data proved failure was administrative, not clinical. The critical attrition vector occurred almost entirely between Prior Authorization (PA) Appeal 1 and Appeal 2. Leadership executed an immediate deployment of targeted Field Reimbursement Managers to these specific clinic clusters, reducing administrative time-to-therapy by 14 days and salvaging $22M in annual at-risk patient initiations.
Veyara BioStrategy was founded to bridge the gap between high-level management consulting and rigorous computational data science.
Traditional strategy firms charge a premium to support massive onshore real estate and layers of junior generalists. We reject this model.
We operate a concentrated Global Intelligence Hub exclusively in Pune, India. This deliberate architectural choice allows us to deploy elite, pharma-native data science talent and senior strategic guidance while shielding our clients from the overhead of legacy consulting models. You pay for clarity and computational horsepower, not real estate.
Our partners bring experience from top-tier global strategy firms, and our technical teams are native to healthcare claims, EMR, and enterprise environments like Veeva and Snowflake.
The Confidential Diagnostic Briefing.
We begin all engagements with a 45-minute working session with a senior practice partner under reciprocal NDA. We will evaluate the constraints, the data availability, and tell you immediately if we can solve it.
Please direct all scoping inquiries to our advisory desk. We recommend including a brief overview of the therapeutic area and the specific commercial decision required.
[email protected] Click to draft email